Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by Gorf79on Jul 20, 2022 11:01pm
252 Views
Post# 34839137

RE:RE:RE:RE:RE:Don't sell your shares!

RE:RE:RE:RE:RE:Don't sell your shares!

Well Said Tech one.

And you are spot on in your take, particularly with Dialco, although I think your valuation is light by two thirds.

PMX and Baxter seem to be dominating the posts this week. It is easy to lose track of the recently COMMERCIAL Dialco division, and their own two pronged approach to the ownership of the in in-clinic/hospital and home dialysis market for years to come.


DIALCO the WHOLLY OWNED DIALYSIS DIVISION: FDA Approved, Cloud connected, touch screen controlled, cost effective, excellent safety profile, easy to use, instantaneous monitoring by client's physician, innovative, clean sheet design, intuitive, 10 year competitive regulatory lead, portable and set to absolutely hammer the competition!!!.... And it did with the very recent ARC Dialysis deal!

That is an oversight that is easy to make if you are a new or prospective investor.

If we had an attentive, non hibernating analyst Stockhouse would not be the only source of opinion on Spectral but such is the case.

Thanks again!

<< Previous
Bullboard Posts
Next >>